November 22, 2013
Venatorx Pharmaceuticals has completed a Series A financing round of approximately $3.5M from private investors to complement its other sources of funding and help advance its novel discovery and development programs.
October 22, 2013
Venatorx Pharmaceuticals received an investment of $8.9M from the Wellcome Trust Translation Fund for the “Development of novel small molecules for the treatment of antibiotic resistant bacterial infections.
September 16, 2013
Venatorx Pharmaceuticals was elected to execute a research and development contract around proprietary compounds that address resistant NIAID Category A, B, and C pathogens. The contract award is for up to $21.2M.
September 1, 2013
Venatorx Pharmaceuticals was awarded a Phase 2 SBIR Grant for novel approaches to address multi-drug resistant gram-negative infections. Venatorx may receive up to $3M of funding under the grant.
August 1, 2013
Mr. Milano is the President, Chief Executive Officer, and Chairman of the Board of Directors of ViroPharma.
May 20, 2013
Mr. Felker brings over 20 years of experience in biotechnology, pharmaceutical, and diagnostics, spanning business development, operations, and venture capital.